Sign in

You're signed outSign in or to get full access.

Wenhua Zhang

About Wenhua Zhang

Wenhua Zhang, age 55, has served as an independent director of Mountain Crest Acquisition Corp. V since April 2021. He is a Partner at Azia Capital Fund LP (since October 2014) and previously held investment roles at T. Rowe Price, Bain Capital, Harvard Management Company, and Newport Asia LLC; he earned an MBA from the Wharton School in May 2001 .

Past Roles

OrganizationRoleTenureCommittees/Impact
Mountain Crest Acquisition Corp. (MCAC)DirectorJan 2020 – Feb 2021Not disclosed
Mountain Crest Acquisition Corp. II (MCAD)DirectorOct 2020 – Oct 2021Not disclosed
Mountain Crest Acquisition Corp. III (MCAE)DirectorMar 2021 – Feb 2023Not disclosed
Mountain Crest Acquisition Corp. IV (MCAF)DirectorMar 2021 – Mar 2024Not disclosed

External Roles

OrganizationRoleTenureNotes
Azia Capital Fund LPPartnerOct 2014 – PresentPrivate investment firm
T. Rowe PriceVP Equity Research (TMT)Aug 2001 – May 2008Buy-side research
Bain Capital (Brookside Fund)DirectorJul 2008 – Dec 2010Long/short equity
Harvard Management CompanySVP & Portfolio ManagerFeb 2011 – Aug 2012Endowment investing
Newport Asia LLCPartner & Portfolio ManagerOct 2012 – Oct 2014Asia growth equities
EducationMBA (Wharton)May 2001Finance & tech innovation

Board Governance

  • Independence: Board determined Zhang is “independent” under Nasdaq and SEC rules .
  • Committee assignments:
    • Audit Committee: Member; committee chaired by Dr. Todd Milbourn .
    • Compensation Committee: Chair; committee includes Haight and Milbourn .
  • Nominating/Governance: No standing committee; independent directors (including Zhang) recommend nominees when needed .
  • Executive sessions: Independent directors hold regularly scheduled meetings with only independent directors present .

Fixed Compensation

ComponentDetailAmountNotes
Director cash compensationNone disclosedCompany states no executive cash comp; director fees not disclosed .
Expense reimbursementReimbursement of out-of-pocket board-related expensesNot capped (subject to cash outside trust)Reviewed by Audit Committee; payable only if a business combination closes or from cash outside trust .
Administrative support agreementOffice/admin fee paid to SponsorUp to $10,000/monthNot director pay; corporate overhead arrangement .

Other Directorships & Interlocks

CompanyPublic?Relationship/InterlockTenure
MCAC (PLBY transaction predecessor)YesShared Mountain Crest sponsor ecosystemJan 2020 – Feb 2021
MCAD (Better Therapeutics transaction predecessor)YesShared Mountain Crest sponsor ecosystemOct 2020 – Oct 2021
MCAE (ETAO transaction predecessor)YesShared Mountain Crest sponsor ecosystemMar 2021 – Feb 2023
MCAF (CH AUTO transaction predecessor)YesShared Mountain Crest sponsor ecosystemMar 2021 – Mar 2024

Expertise & Qualifications

  • Buy-side and portfolio management expertise across global equities and Asia growth strategies .
  • Sell-side/buy-side research leadership in TMT sectors .
  • MBA in finance and technology innovation (Wharton), supporting compensation and strategy governance work .
  • Service across multiple SPAC boards provides transaction process familiarity .

Equity Ownership

| Metric | Oct 10, 2024 | Oct 7, 2025 | |---|---|---|---| | Total shares outstanding | 3,320,221 | 2,902,004 | | Wenhua Zhang – shares beneficially owned | 2,400 | 2,400 | | Ownership % of outstanding | <1% | <1% |

  • No disclosure of vested vs. unvested shares, options, or pledged shares for Zhang .
  • Founder Shares are held by the Sponsor (controlled by CEO Suying Liu), subject to escrow and release conditions; not owned by Zhang .

Governance Assessment

  • Committee leadership: Serving as Compensation Committee Chair and Audit Committee member positions Zhang at the core of pay oversight and financial controls, supporting board effectiveness in a lean SPAC structure .
  • Independence and engagement: Board has explicitly designated Zhang independent; independent directors meet in executive session and must approve any business combination, strengthening checks on sponsor-related transactions .
  • Ownership alignment: Zhang’s beneficial ownership is 2,400 shares (<1%), which is modest versus Sponsor control (≈71% held via Mountain Crest Global Holdings LLC), limiting personal economic alignment compared to Sponsor interests .
  • Related-party exposure: The company relies on Sponsor financing (interest-free promissory notes) and converts Sponsor loans into equity; these were approved by the Audit Committee (on which Zhang serves), requiring continued vigilance on conflicts and fair terms .
  • Listing and market risks: Securities currently quoted on OTC (after 2024 Nasdaq delisting risk), triggering potential “penny stock” rules that may impair liquidity and investor confidence around any transaction close .
  • Regulatory sensitivity: Company cautions that having a non-U.S. citizen director may invite CFIUS review for certain U.S. targets, potentially delaying or prohibiting combinations under FIRRMA—this is a general board risk factor not tied to a named director .

RED FLAGS

  • Sponsor dominance of voting power (~71%) and extensive related-party loans and conversions increase perceived conflicts and pressure to complete a deal rather than liquidate .
  • OTC quotation and “penny stock” regime may reduce liquidity and attractiveness as a merger partner; threatens post-close listing requirements for any combined company .
  • Repeated extensions of the business combination period and reliance on Sponsor advances heighten timeline and financing dependency risks .

Compensation Committee Analysis

  • Composition: All independent directors; Zhang serves as Chair .
  • Consultant use: Committee may retain independent compensation consultants, counsel, or advisors; independence of advisors must be considered per NASDAQ/SEC factors .
  • Interlocks: None disclosed; committee members have not been officers or employees of the company, and executives did not serve on other entities’ committees that would create interlocks .

Notes on Missing Disclosures

  • No explicit disclosure of director meeting attendance rates, board/committee fees, equity grants for directors, or director ownership guidelines .
  • No Form 4 insider trading data is provided in these proxy statements; beneficial ownership tables indicate static holdings for directors .